The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - Shares of Medtronic (NYSE:MDT) are expected to be strong today and through the company’s fiscal 1Q 2013 earnings report next week, with a big upgrade … Continue Reading
Read nowLong Ideas - After yesterday’s news from Idenix Pharmaceuticals (NASDAQ:IDIX) and the ensuing 30% sell-off, Gilead Sciences (NASDAQ:GILD) saw a small decline in share price. Gilead’s lead Hepatitis … Continue Reading
Read nowLong Ideas - Pfizer’s (NYSE:PFE) developmental drug tofacitinib, originally indicated for Rheumatoid Arthirits, showed positive trial results in treating ulcerative colitis and has been moved into a Phase … Continue Reading
Read nowLong Ideas - Idenix Pharmaceuticals (NASDAQ:IDIX) announced today that the FDA has placed its lead compound for hepatitis C, IDX-184, on partial clinical hold. According to IDIX, the … Continue Reading
Read now- Lexicon Pharmaceuticals (NASDAQ:LXRX) released findings from two separate Phase I trials this morning for Rheumatoid Arthritis and glaucoma. LX2931 was studied for its safety and … Continue Reading
Read now- Neuralstem, Inc. (NYSEAMEX:CUR) investors will have noted the biotech company’s slow share decline this year. From September 2011’s high of $1.52, shares took an ambling … Continue Reading
Read now- The battle continues in activist-investor Carl Icahn’s fevered examination of Forest Laboratories (NYSE:FRX). Today’s proxy vote will be this year’s penultimate decision; shareholders will be … Continue Reading
Read now
